Research loss in Pfizer-Wyeth deal

Pfizer's $68 billion merger with Wyeth, which officially linkurl:commences today,;http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp?rssUrl=http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1016273&newsId=20091015006478&newsLang=en will mean the loss of almost 20,000 jobs, the company has said, and analysts predict research could take a hard hit. The deal involves combining laboratories of the once-competing companies. Martin Mackay, pres

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Pfizer's $68 billion merger with Wyeth, which officially linkurl:commences today,;http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp?rssUrl=http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1016273&newsId=20091015006478&newsLang=en will mean the loss of almost 20,000 jobs, the company has said, and analysts predict research could take a hard hit. The deal involves combining laboratories of the once-competing companies. Martin Mackay, president of Pfizer Global Research and Development, linkurl:told Bloomberg News;http://www.bloomberg.com/apps/news?pid=20601103&sid=aAh8pjthSok8 that the merger would likely involve cuts in research spending. Though he didn't specify how much, analyst estimates put the number at as much as $3 billion, Bloomberg News reports -- which will translate into job losses. "These big acquisitions don't do a thing for research," linkurl:Kenneth Kaitin,;http://csdd.tufts.edu/About/ResearchStaff.asp director of the Tufts Center for the Study of Drug Development, told Bloomberg News. "I don't think anyone should be fooled into thinking these big acquisitions have anything to do with innovation or increased research and development capacity." As a result of the merger, many facilities will be shuttered. The Wall Street Journal Health Blog is linkurl:compiling reports;http://blogs.wsj.com/health/2009/10/16/pfizer-wyeth-which-sites-are-closing-which-are-staying-open/ on the fate of individual Wyeth and Pfizer locations.
**__Related stories:__***linkurl:Merck and Schering-Plough to merge;http://www.the-scientist.com/blog/display/55497/
[9th March 2009]*linkurl:How to save biotech;http://www.the-scientist.com/news/display/55425/
[17th February 2009]*linkurl:The urge to merge;http://www.the-scientist.com/article/display/14931/
[13th September 2004]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Alla Katsnelson

    This person does not yet have a bio.
Share
Image of small blue creatures called Nergals. Some have hearts above their heads, which signify friendship. There is one Nergal who is sneezing and losing health, which is denoted by minus one signs floating around it.
June 2025, Issue 1

Nergal Networks: Where Friendship Meets Infection

A citizen science game explores how social choices and networks can influence how an illness moves through a population.

View this Issue
Unraveling Complex Biology with Advanced Multiomics Technology

Unraveling Complex Biology with Five-Dimensional Multiomics

Element Bioscience Logo
Resurrecting Plant Defense Mechanisms to Avoid Crop Pathogens

Resurrecting Plant Defense Mechanisms to Avoid Crop Pathogens

Twist Bio 
The Scientist Placeholder Image

Seeing and Sorting with Confidence

BD
The Scientist Placeholder Image

Streamlining Microbial Quality Control Testing

MicroQuant™ by ATCC logo

Products

The Scientist Placeholder Image

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

parse-biosciences-logo

Pioneering Cancer Plasticity Atlas will help Predict Response to Cancer Therapies

waters-logo

How Alderley Analytical are Delivering eXtreme Robustness in Bioanalysis